Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer

Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer

BackgroundFirst-line treatment with nivolumab plus ipilimumab (N+I) or nivolumab plus ipilimumab with two cycles of chemotherapy (N+I+chemotherapy) improve overall survival and progression-free survival for patients with metastatic non-small cell lung cancer (NSCLC), yet researchers have not concomi...

Full description

Bibliographic Details
Main Authors: Szu-Chun Yang, Natalia Kunst, Cary P. Gross, Jung-Der Wang, Wu-Chou Su, Shi-Yi Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-12-01
Series:Frontiers in Oncology
Subjects:
cost-effectiveness
immunotherapy
non-small cell lung cancer
nivolumab
ipilimumab
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.760686/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.760686/full

Similar Items